Enric Esmatjes

Enric Esmatjes

Auto-generated profile, based on publicly available information

Enric Esmatjes

Diabetes Unit, Endocrinology and Nutrition Department, Hospital Clínic, Barcelona, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2005 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
MPMarc A. Pohl
Marc A. Pohl
SBSamuel Blumenthal
Samuel Blumenthal
DCDaniel J. Cordonnier
Daniel J. Cordonnier
FAFernando De Alvaro
Fernando De Alvaro
GDGiacomo DeFerrari
Giacomo DeFerrari
ELEdmund J. Lewis
Edmund J. Lewis
Elevated arterial pressure is a major risk factor for progression to ESRD in diabetic nephropathy. However, the component of arterial pressure and level of BP control for optimal renal outcomes are disputed. Data from 1590 hypertensive patients with type 2 diabetes in the Irbesartan Diabetic Nephropathy Trial (IDNT), a randomized, double-blind, placebo-controlled trial performed in 209 clinics worldwide, were examined, and the effects of baseline and mean follow-up systolic BP (SBP) and diastolic BP and the interaction of assigned study medications (irbesartan, amlodipine, and placebo) on progressive renal failure and all-cause mortality were assessed. Other antihypertensive agents were added to achieve predetermined BP goals. Entry criteria included elevated baseline serum creatinine concentration up to 266 μmol/L (3.0 mg/dl) and urine protein excretion >900 mg/d. Baseline BP averaged 159/87 ± 20/11 mmHg. Median patient follow-up was 2.6 yr. Follow-up achieved SBP most strongly predicted renal outcomes. SBP >149 mmHg was associated with a 2.2-fold increase in the risk for doubling serum creatinine or ESRD compared with SBP <134 mmHg. Progressive lowering of SBP to 120 mmHg was associated with improved renal and patient survival, an effect independent of baseline renal function. Below this threshold, all-cause mortality increased. An additional renoprotective effect of irbesartan, independent of achieved SBP, was observed down to 120 mmHg. There was no correlation between diastolic BP and renal outcomes. We recommend a SBP target between 120 and 130 mmHg, in conjunction with blockade of the renin-angiotensin system, in patients with type 2 diabetic nephropathy.

1 July 2005 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
TBTomas Berl
Tomas Berl
LHLawrence G. Hunsicker
Lawrence G. Hunsicker
JLJulia B. Lewis
Julia B. Lewis
MPMarc A. Pfeffer
Marc A. Pfeffer
JPJerome G. Porush
Jerome G. Porush
ELEdmund J. Lewis
Edmund J. Lewis
Elevated arterial pressure enhances the risk for cardiovascular (CV) events in patients with diabetic nephropathy. The optimal BP and the component of the elevated BP that affect the risk have not been defined. A post hoc analysis was performed to assess the impact of achieved systolic, diastolic, and pulse pressures on CV outcomes in 1590 adults who had overt diabetic nephropathy and were enrolled in the Irbesartan Diabetic Nephropathy Trial (IDNT) and had a baseline serum creatinine above the normal range, up to 266 μmol/L (3.0 mg/dL), 24-h urine protein >900 mg/d, and at least 6 mo of follow-up. Patients were randomized to irbesartan, amlodipine, or placebo, with other antihypertensive agents to a BP goal of ≤135/85 mmHg. Progressively lower achieved systolic BP (SBP) to 120 mmHg predicted a decrease in CV mortality and congestive heart failure (CHF) but not myocardial infarctions (MI). A SBP below this threshold was associated with increased risk for CV deaths and CHF events. Achieved diastolic BP <85 mmHg was associated with a trend to increase in all-cause mortality, significant increase in MI, but decreased risk for strokes. Increased pulse pressure predicted increased all-cause mortality, CV mortality, MI, and CHF. It is concluded that achieved SBP approaching 120 mmHg and diastolic BP of 85 mmHg are associated with the best protection against CV events in these patients. BP ≤120/85 may be associated with an increase in CV events.

1 July 1996 in Journal of Hepatology
Verified
Journal Article
Closed access
MNMiquel Navasa
Miquel Navasa
JBJavier Bustamante
Javier Bustamante
CMClaudio Marroni
Claudio Marroni
EGEleazar González
Eleazar González
HAHernán Andreu
Hernán Andreu
JRJoan Rodés
Joan Rodés

1 March 2009 in Schizophrenia Bulletin
Verified
Journal Article
Closed access
EFE. Fernandez-Egea
E. Fernandez-Egea
MBMiquel Bernardo
Miquel Bernardo
CHC. M. Heaphy
C. M. Heaphy
JGJ. K. Griffith
J. K. Griffith
EPEduard Parellada
Eduard Parellada
BKB. Kirkpatrick
B. Kirkpatrick
Recent studies suggest that in addition to factors such as treatment side effects, suicide, and poor health habits, people with schizophrenia may have an increased risk of diabetes prior to antipsychotic treatment. Diabetes is associated with an increased pulse pressure (PP) and a shortened telomere. We tested the hypothesis that prior to antipsychotic treatment, schizophrenia and related disorders are associated with a shortened telomere, as well as an increased PP. Telomere content (which is highly correlated with telomere length) and PP were measured in newly diagnosed, antipsychotic-naive patients with schizophrenia and related disorders on first clinical contact and in matched control subjects. Both groups were also administered an oral glucose tolerance test. Compared with control subjects, the patients with psychosis had decreased telomere content and an increased PP. As previously reported, they also had increased glucose concentrations at 2 hours. These differences could not be attributed to differences in age, ethnicity, smoking, gender, body mass index, neighborhood of residence, socioeconomic status, aerobic conditioning, or an increased cortisol concentration in the psychotic subjects. These results suggest that prior to antipsychotic use, nonaffective psychosis is associated with reduced telomere content and increased PP, indices that have been linked to an increased risk of diabetes and hypertension.

1 November 2004 in Kidney International
Verified
Journal Article
Closed access
NANagesh S. Anavekar
Nagesh S. Anavekar
DGDaniel J. Gans
Daniel J. Gans
TBTomas Berl
Tomas Berl
RRRichard D. Rohde
Richard D. Rohde
WCWilliam Cooper
William Cooper
MPMarc A. Pfeffer
Marc A. Pfeffer

2 June 2008 in Schizophrenia Research
Verified
Journal Article
Closed access
EFEmilio Fernandez-Egea
Emilio Fernandez-Egea
MBMiquel Bernardo
Miquel Bernardo
EPEduard Parellada
Eduard Parellada
AJAzucena Justicia
Azucena Justicia
CGClemente Garcia-Rizo
Clemente Garcia-Rizo
BKBrian Kirkpatrick
Brian Kirkpatrick